Francica JR, Zak DE, Linde C, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 2017;1(25):2329-2342.

On page 2329 in the 28 November 2017 issue, the byline and author affiliations omitted the 20th author, Andres Salazar. The byline and author affiliations should have read:

Joseph R. Francica,1,* Daniel E. Zak,2,* Caitlyn Linde,3 Emilio Siena,4,5 Carrie Johnson,2 Michal Juraska,6 Nicole L. Yates,7 Bronwyn Gunn,3 Ennio De Gregorio,4,5 Barbara J. Flynn,1 Nicholas M. Valiante,4,8 Padma Malyala,4 Susan W. Barnett,4,9 Pampi Sarkar,4 Manmohan Singh,4,10 Siddhartha Jain,4 Margaret Ackerman,11 Munir Alam,7 Guido Ferrari,7 Andres Salazar,12 Georgia D. Tomaras,7 Derek T. O’Hagan,4,5 Alan Aderem,2 Galit Alter,3 and Robert A. Seder1

1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; 2The Center for Infectious Disease Research, Seattle, WA; 3Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA; 4Novartis Vaccines and Diagnostics, Cambridge, MA; 5GlaxoSmithKline, Siena, Italy; 6Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 7Duke Human Vaccine Institute, Durham, NC; 8Moderna Therapeutics, Cambridge, MA; 9Bill & Melinda Gates Foundation, Washington, DC; 10Takeda Pharmaceuticals, Cambridge, MA; 11Thayer School of Engineering, Dartmouth College, Hanover, NH; and 12Oncovir, Inc, Washington, DC

On page 2339, under “Authorship,” the contribution paragraph should have read, “J.R.F., D.E.Z., G.A., and R.A.S. conceived the study and wrote the paper; E.S., N.M.V., P.M., E.D.G., S.W.B., P.S., M.S., S.J., A.S., and D.T.O. developed the vaccine formulations; J.R.F., C.L., N.L.Y., B.G., B.J.F., M. Ackerman, M. Alam, G.F., and G.D.T. designed and carried out experiments; C.J. and D.E.Z. performed the transcriptional analyses; M.J. performed half-life modeling; and A.A., D.E.Z., G.A., and R.A.S. gave conceptual advice and project oversight.” The conflict-of-interest paragraph under “Authorship” should have read, “E.S., N.M.V., P.M., E.D.G., S.W.B., P.S., M.S., S.J., and D.T.O. were employees of Novartis Vaccines at this study’s conception. A.S. is the chief executive officer and chief science officer of and owns stock in Oncovir, Inc, the company that makes pIC:LC (Hiltonol). The remaining authors declare no competing financial interests.”

The errors have been corrected in the published article.

  • Submitted February 15, 2018.
  • Accepted February 15, 2018.